Umesh Modi is a chartered accountant, and Pamini Jatheeskumar is a chartered certified accountant at Silver Levene...
  Don Lavoie is alcohol programme manager at Public Health England and Gul Root is lead...
Don Lavoie is alcohol programme manager at Public Health England and Gul Root is lead pharmacist, Health and Wellbeing Directorate, Public Health England
More inWhite Papers  

celecoxibNovember 17 2014

Generic versions of celecoxib have been launched in the UK following the expiry of the patent on Pfizer’s Celebrex. Among the generics manufacturers launching the newly off-patent drug are Actavis and Teva.

Celecoxib is a selective inhibitor of cyclo-oxygenase-2 and is licensed for the relief of pain in osteoarthritis, rheumatoid arthritis, and ankylosing spondylitis.

Teva points out: “In the UK, around 10 million people are affected by a form of arthritis, costing the NHS in England some £5 billion every year. The introduction of generic versions of medicines saves the healthcare system considerable amounts of money.

“The average cost to the NHS of a generic medicine is £3.79, while the average cost of a branded medicine is £19.73. These funds can be used to pay for other, more expensive treatments and services that patients need, including funding the research into new treatments and medicines.”

The manufacturers are making celecoxib available in two strengths of capsules - 100mg in packs of 60, and 200mg in 30s.

Links:

Actavis announcement

Teva announcment

July 31 2018 General practices employing pharmacists are citing improved capacity to see patients and workload changes as the main benefits of the scheme.
July 25 2018 Switching to sulfonylureas in type 2 diabetes has been linked with an increased risk of complications compared with staying on metformin, a BMJ study has concluded. However, the study has...